Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYLOREL vs DIAZOXIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits sympathetic vasoconstriction, reducing peripheral vascular resistance and blood pressure.
Diazoxide is a potassium channel activator that opens ATP-sensitive potassium channels in pancreatic beta cells, inhibiting insulin secretion. It also causes peripheral vasodilation by activating potassium channels in vascular smooth muscle.
Hypertension,Benign prostatic hyperplasia
Treatment of hypoglycemia due to hyperinsulinism (e.g., islet cell adenoma, nesidioblastosis, extrapancreatic malignancy),Off-label: Management of hypertensive emergencies (IV form; rarely used due to adverse effects)
10 mg orally twice daily, titrated to 20-40 mg twice daily based on blood pressure response.
Hypertension: 1-3 mg/kg IV bolus, up to 150 mg, repeated every 5-15 minutes to achieve desired blood pressure. Hyperinsulinemic hypoglycemia: 3-8 mg/kg/day PO divided every 8-12 hours.
Approximately 12-15 hours; clinically, steady-state achieved in 2-3 days.
Terminal half-life: 20-36 hours (adults), 9-24 hours (children). Context: shorter after IV bolus due to redistribution; prolonged in renal impairment.
Extensively metabolized in the liver via O-demethylation and conjugation; CYP450 enzymes involved (CYP2D6, CYP3A4).
Hepatic metabolism with excretion of metabolites in urine and bile. Minor metabolism via hydroxylation and glucuronidation.
Primarily renal (50-60% unchanged) and biliary/fecal (40-50%).
Renal: ~50% unchanged; minor biliary/fecal excretion.
90-95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
>90% bound to serum albumin.
0.5-0.7 L/kg; indicates distribution into total body water.
0.2-0.4 L/kg; small Vd indicates limited extravascular distribution.
85-90% after oral administration.
Oral: ~100% (well absorbed); IV: 100%.
No adjustment needed for mild to moderate renal impairment (GFR 30-89 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor blood pressure closely.
No specific GFR-based dose adjustments are required; however, accumulation may occur in severe renal impairment. Use with caution and monitor blood pressure and electrolytes.
For Child-Pugh Class A: no adjustment. For Class B: reduce starting dose to 5 mg twice daily, titrate cautiously. For Class C: avoid use due to lack of safety data.
No specific Child-Pugh based dose adjustments available. Use with caution in hepatic impairment due to potential for increased adverse effects.
Not recommended in pediatric patients due to lack of safety and efficacy data.
Hyperinsulinemic hypoglycemia: 10-25 mg/kg/day PO divided every 8-12 hours. Hypertensive emergency: 1-3 mg/kg IV bolus, may repeat every 5-15 minutes.
Start at 5 mg twice daily, titrate slowly; monitor for orthostatic hypotension and electrolyte imbalances due to age-related changes in renal function and sympathetic response.
Initial dose reduction recommended due to increased sensitivity to antihypertensive effects and higher risk of hypotension and electrolyte disturbances. Start at lower end of dosing range and titrate carefully.
None
None.
Syncope and orthostatic hypotension,Priapism,Intraoperative floppy iris syndrome,Use in patients with impaired hepatic function
Fluid retention and edema, especially in patients with cardiac or renal impairment,Hyperglycemia (may require insulin or oral hypoglycemics),Hypotension (with IV administration),Cerebral ischemia or infarction (with rapid IV injection),Tachycardia and arrhythmias
Hypersensitivity to guanadrel or similar drugs,Concomitant use with MAO inhibitors
Hypersensitivity to diazoxide or thiazides,Functional hypoglycemia (e.g., reactive hypoglycemia),Severe hypotension,Cardiogenic shock
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as guanethidine may potentiate pressor effects. Also avoid excessive alcohol consumption due to additive hypotensive effects. Take with food to reduce GI upset.
Avoid grapefruit juice; may increase diazoxide levels. Limit high-sodium foods to reduce fluid retention. Alcohol may enhance hypotensive effects.
Pregnancy Category C. First trimester: No adequate studies, but potential for fetal harm based on animal data (skeletal abnormalities, reduced fetal weight at high doses). Second and third trimesters: May cause fetal bradycardia, hypotension, and reduced placental perfusion; avoid use due to risk of oligohydramnios and fetal renal impairment.
In animals, diazoxide is teratogenic at high doses, producing fetal abnormalities including skeletal and visceral malformations. Human data are limited; however, case reports have described fetal/neonatal adverse effects such as hypertrichosis, alopecia, and transient hyperglycemia after in utero exposure. Use in pregnancy only if clearly needed, weighing benefit versus fetal risk. There is no clear evidence of increased risk for major birth defects, but data are insufficient to rule out risk.
Excreted in human milk in small amounts; M/P ratio unknown. Use caution in nursing mothers, especially in preterm neonates due to potential for hypotension and bradycardia. Monitor infant for sedation, poor feeding, and hypotonia.
Diazoxide is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.17–0.23 based on limited data. Milk concentrations are low relative to therapeutic doses, but potential for infant toxicity (e.g., hyperglycemia, hypertrichosis) exists. Caution advised; if used, monitor infant for signs of hyperglycemia or other adverse effects.
Due to increased plasma volume and renal clearance in pregnancy, guanfacine levels may decrease; however, dose adjustment not routinely recommended due to limited data. Use lowest effective dose. Avoid use in preeclampsia or volume-depleted states. No specific guidelines for dose increase.
Data are insufficient to guide specific dose adjustments during pregnancy. Pregnancy may increase clearance of diazoxide; however, no formal pharmacokinetic studies are available. Clinical monitoring of therapeutic effect and adverse effects is recommended; dose adjustment may be needed based on blood glucose response and tolerability.
HYLOREL (guanethidine) is a potent adrenergic neuron blocker used primarily for moderate to severe hypertension. Its use is limited due to orthostatic hypotension and dose-related side effects. Initiate at low doses (10 mg/day) and titrate slowly. Avoid in patients with pheochromocytoma or MAOI use within 14 days. Monitor for profound orthostasis, especially upon waking and after exercise. May cause diarrhea due to increased GI motility. Combine with a diuretic to reduce dose requirements and enhance efficacy.
Diazoxide is a potassium channel opener used for hypertensive emergencies and hypoglycemia due to hyperinsulinism. Administer intravenously for hypertension; oral form used for hypoglycemia. Rapid injection may cause hypotension; monitor blood pressure closely. Can cause sodium and water retention; co-administer with a diuretic. Contraindicated in patients with hypersensitivity to thiazides or sulfonamides.
Take exactly as prescribed; do not stop abruptly as this may cause rapid blood pressure increase.,Arise slowly from sitting or lying to prevent dizziness and fainting. Avoid sudden position changes.,Avoid alcohol and over-the-counter cold or allergy medications unless approved by your doctor.,May cause drowsiness; use caution when driving or operating machinery.,Report persistent dizziness, fainting, or severe diarrhea to your healthcare provider.,Maintain adequate fluid intake, but avoid excessive salt unless directed.,Inform all healthcare providers of your use of this medication before any surgery.
Take oral diazoxide exactly as prescribed, usually every 8-12 hours.,Monitor blood glucose regularly, especially if diabetic.,Report symptoms of fluid retention (swelling, weight gain) or hypotension (dizziness, fainting).,Avoid alcohol and limit sodium intake.,Do not stop abruptly; taper under medical supervision.
No interactions on record
"Diazoxide, a potassium channel opener that causes arteriolar vasodilation, can potentiate the hypotensive effects of mecamylamine, a ganglionic blocker that inhibits sympathetic and parasympathetic autonomic ganglia. This additive or synergistic reduction in blood pressure may lead to severe hypotension, orthostatic dizziness, syncope, or impaired perfusion of vital organs. Patients should be closely monitored for excessive blood pressure drops, especially during initiation or dose adjustments of either agent."
"Diazoxide, a potassium channel activator used for hypertensive emergencies, and nitrendipine, a dihydropyridine calcium channel blocker, both exert potent vasodilatory effects through distinct mechanisms. Concurrent use can lead to additive or synergistic reduction in systemic vascular resistance, resulting in profound hypotension, reflex tachycardia, and potential end-organ hypoperfusion. This interaction is particularly risky in patients with compromised cardiovascular function or those receiving other antihypertensive agents."
"Diazoxide, a direct vasodilator used for hypertensive emergencies, and metoprolol, a beta-1 selective adrenergic antagonist, exhibit additive hypotensive effects. Diazoxide-induced reduction in peripheral vascular resistance combined with metoprolol's negative chronotropic and inotropic actions can lead to profound bradycardia and hypotension. Clinically, this may result in dizziness, syncope, or cardiovascular collapse, particularly in patients with compromised cardiac function or during rapid dose escalation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYLOREL vs DIAZOXIDE, answered by our medical review team.
HYLOREL is a Antihypertensive Agent that works by Selective alpha-1 adrenergic receptor antagonist; inhibits sympathetic vasoconstriction, reducing peripheral vascular resistance and blood pressure.. DIAZOXIDE is a Antihypertensive Agent that works by Diazoxide is a potassium channel activator that opens ATP-sensitive potassium channels in pancreatic beta cells, inhibiting insulin secretion. It also causes peripheral vasodilation by activating potassium channels in vascular smooth muscle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYLOREL and DIAZOXIDE depend on the specific clinical indication. These are both Antihypertensive Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYLOREL is: 10 mg orally twice daily, titrated to 20-40 mg twice daily based on blood pressure response.. The standard adult dose of DIAZOXIDE is: Hypertension: 1-3 mg/kg IV bolus, up to 150 mg, repeated every 5-15 minutes to achieve desired blood pressure. Hyperinsulinemic hypoglycemia: 3-8 mg/kg/day PO divided every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYLOREL and DIAZOXIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYLOREL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies, but potential for fetal harm based on animal data (skeletal abnormalities, reduced fetal weight at high doses). Second a. DIAZOXIDE is classified as Category C. In animals, diazoxide is teratogenic at high doses, producing fetal abnormalities including skeletal and visceral malformations. Human data are limited; however, case reports have . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.